Abstract Background The aim of this study was to evaluate the predictive power of the absorbed dose to kidneys after the first course of treatment with [177Lu]-DOTA-TATE for neuroendocrine tumors (NETs) on the cumulative kidney absorbed dose after 3 or 4 cycles of treatment. Post-treatment scans (PTS) are acquired after each cycle of peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE for personalized radiation dosimetry in order to ensure a cumulative absorbed dose to kidneys under a safety threshold of 25 Gy. One hundred eighty-seven patients who completed treatment with [177Lu]-DOTA-TATE and underwent PTS for dosimetry calculation were included in this retrospective study. The correlation between the cumulative absorbed d...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Copyright © 2013 F. Guerriero et al. This is an open access article distributed under the Creative C...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Background: Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory appr...
Purpose: To present data from an interim analysis of a Phase II trial designed to determine the feas...
International audienceRationale: Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE (...
Purpose Assessment of kidney function evolution after Y-90-DOTATOC peptide receptor radionuclide the...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded p...
Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressin...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Kidney dosimetry in 177Lu and 90Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the pep...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Copyright © 2013 F. Guerriero et al. This is an open access article distributed under the Creative C...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...
Radiation dose to the kidneys (kidney dose) in 177Lu-DOTATATE - Peptide Receptor Radionuclide Therap...
Abstract Background Peptide receptor radionuclide therapy (PRRT) with [177Lu]-DOTA-TATE is an effect...
Purpose Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingl...
Background: Recently, 177Lu-dotatate therapy for neuroendocrine tumours has received regulatory appr...
Purpose: To present data from an interim analysis of a Phase II trial designed to determine the feas...
International audienceRationale: Peptide receptor radionuclide therapy (PRRT) with 177 Lu-DOTATATE (...
Purpose Assessment of kidney function evolution after Y-90-DOTATOC peptide receptor radionuclide the...
BACKGROUND: Lu-177-(DOTAO,Tyr3) octreotate is a new treatment modality for disseminated neuroendocri...
PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded p...
Peptide receptor radionuclide therapy for the internal radiation of neuroendocrine tumours expressin...
Purpose: Peptide receptor radionuclide therapy with 177Lu-DOTATATE has become a standard treatment m...
Kidney dosimetry in 177Lu and 90Y PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the pep...
Nephrotoxicity is the major limiting factor during therapy with the radiolabeled somatostatin analog...
Copyright © 2013 F. Guerriero et al. This is an open access article distributed under the Creative C...
Abstract Background Kidney dosimetry after peptide receptor radionuclide therapy using 177Lu-labelle...